Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Kevin Charles Gorman net worth and biography

Kevin Gorman Biography and Net Worth

CEO of Neurocrine Biosciences

Kevin C. Gorman, Ph.D., is a founder and has been employed with the Company since 1993. Dr. Gorman was appointed President and Chief Executive Officer in January 2008 after serving as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He has served on the Board of Directors since January 2008. Dr. Gorman is also a director of Xencor, Inc., a clinical-stage biopharmaceutical company. From 1990 until 1993, Dr. Gorman was a principal at Avalon Medical Partners, L.P., where he was responsible for the early-stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in Immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.

What is Kevin Charles Gorman's net worth?: The estimated net worth of Kevin Charles Gorman is at least $69.69 million as of February 13th, 2024. Dr. Gorman owns 514,596 shares of Neurocrine Biosciences stock worth more than $69,686,590 as of December 23rd. This net worth evaluation does not reflect any other assets that Dr. Gorman may own. Additionally, Dr. Gorman receives an annual salary of $2,050,000.00 as CEO at Neurocrine Biosciences. Learn More about Kevin Charles Gorman's net worth.
How old is Kevin Charles Gorman?: Dr. Gorman is currently 66 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. Learn More on Kevin Charles Gorman's age.
What is Kevin Charles Gorman's salary?: As the CEO of Neurocrine Biosciences, Inc., Dr. Gorman earns $2,050,000.00 per year. Learn More on Kevin Charles Gorman's salary.
How do I contact Kevin Charles Gorman?: The corporate mailing address for Dr. Gorman and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Kevin Charles Gorman's contact information.
Has Kevin Charles Gorman been buying or selling shares of Neurocrine Biosciences?: Kevin Charles Gorman has not been actively trading shares of Neurocrine Biosciences during the last ninety days. Most recently, Kevin Charles Gorman sold 2,832 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $133.02, for a transaction totalling $376,712.64. Following the completion of the sale, the chief executive officer now directly owns 514,596 shares of the company's stock, valued at $68,451,559.92. Learn More on Kevin Charles Gorman's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 43 times. They sold a total of 532,972 shares worth more than $72,984,450.99. The most recent insider tranaction occured on December, 17th when insider Ingrid Delaet sold 1,091 shares worth more than $147,285.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 12/17/2024.

Kevin Charles Gorman Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2024	Sell	2,832	$133.02	$376,712.64	514,596
2/8/2024	Sell	2,274	$134.15	$305,057.10	506,962
2/6/2024	Sell	3,040	$142.18	$432,227.20	504,919
1/31/2024	Sell	2,707	$140.69	$380,847.83	502,188
1/8/2024	Sell	105,835	$132.44	$14,016,787.40	499,754
8/21/2023	Sell	9,328	$107.40	$1,001,827.20	499,754
2/8/2023	Sell	2,274	$104.30	$237,178.20	491,365
2/6/2023	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Sell	2,707	$110.08	$297,986.56	465,278
2/7/2022	Sell	8,710	$80.82	$703,942.20
2/8/2021	Sell	10,466	$116.75	$1,221,905.50	443,249
2/5/2021	Sell	2,422	$114.16	$276,495.52	443,249
1/8/2021	Sell	308,250	$110.22	$33,975,315.00	584,520
11/12/2020	Sell	3,390	$90.78	$307,744.20	441,071
8/5/2020	Sell	3,390	$118.91	$403,104.90	438,021
4/24/2020	Sell	2,906	$99.45	$289,001.70	434,971
2/7/2020	Sell	3,248	$103.35	$335,680.80	432,357
2/5/2020	Sell	5,449	$103.09	$561,737.41	423,351
8/8/2019	Sell	80,000	$95.31	$7,624,800.00	468,508
8/6/2019	Sell	50,911	$95.15	$4,844,181.65	468,508
2/5/2019	Sell	7,614	$88.16	$671,250.24	408,082
5/1/2018	Sell	126,832	$80.75	$10,241,684.00	473,865
2/6/2018	Sell	105,983	$80.25	$8,505,135.75	339,482
1/16/2018	Sell	3,750	$78.89	$295,837.50
5/2/2017	Sell	21,739	$53.23	$1,157,166.97	354,346
4/12/2017	Sell	19,596	$50.42	$988,030.32	332,913
2/6/2017	Sell	3,010	$43.18	$129,971.80	250,542
2/3/2017	Sell	3,125	$42.55	$132,968.75	247,802
1/17/2017	Sell	3,750	$40.65	$152,437.50	244,677
1/10/2017	Sell	3,750	$43.28	$162,300.00	240,927
2/3/2016	Sell	3,125	$38.04	$118,875.00	228,077
1/19/2016	Sell	3,750	$46.70	$175,125.00	224,952
1/11/2016	Sell	3,750	$44.17	$165,637.50	221,202
10/16/2015	Sell	33,500	$47.77	$1,600,295.00	217,452
3/24/2015	Sell	40,000	$41.53	$1,661,200.00
1/16/2015	Sell	3,750	$30.79	$115,462.50
1/12/2015	Sell	3,750	$28.43	$106,612.50
1/8/2015	Sell	25,000	$27.39	$684,750.00
12/19/2014	Sell	70,000	$23.41	$1,638,700.00
1/10/2014	Sell	3,750	$18.57	$69,637.50	180,952
1/7/2014	Sell	108,000	$16.76	$1,810,080.00	177,202

Kevin Charles Gorman Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.95

$132.83

$136.11

50 Day Range

MA: $123.99

$115.08

$136.69

2 Week Range

Now: $135.95

$110.95

$157.98

Volume

758,778 shs

Average Volume

883,497 shs

Market Capitalization

$13.76 billion

P/E Ratio

36.45

Dividend Yield

N/A

Beta

0.34

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Kevin Gorman Biography and Net Worth

What is Kevin Charles Gorman's net worth?

How old is Kevin Charles Gorman?

What is Kevin Charles Gorman's salary?

How do I contact Kevin Charles Gorman?

Has Kevin Charles Gorman been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?